Skip to content
Blerp – Lifestyle
Author:
Propanc Biopharma, Inc.
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
May 19, 2026
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
May 15, 2026
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
May 13, 2026
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
March 24, 2026
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
March 12, 2026
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
March 10, 2026
←
Previous Page
1
2